The pharmacokinetics of amphotericin B were studied in two patients at the conclusion of long-term therapy for disseminated histoplasmosis. The distribution kinetics of this drug were adequately described by a three-compartment mamillary model with a total distribution volume averaging 4 Amphotericin B assay. Serum and urine specimens were bioassayed by using radial growth inhibition of Paecilomyces variotii, as reported previously (5). The lower limit of accurate detection of amphotericin B by this assay is 0.1 ,g/ml (5). Urine specimens were kept at 4°C during collection of 24-h samples. Once collected, both urine and serum were stored at -70°C before assay.
Dose recommendations for the safe and effective use of amphotericin B have evolved from careful clinical observation of the response of patients who have been treated with this drug (5, 3, 9) . The present investigation provides a rational pharmacokinetic basis for analysis of intravenous treatment regimens currently in vogue. This approach is similar to that previously applied to a description of the pharmacokinetics of intrathecally administered amphotericin B (1) and hopefully will serve as a framework for the design of improved treatment regimens with this drug in the future.
MATERIALS AND METHODS Patients. Two patients were studied at the conclusion of a course of amphotericin B given intravenously. Both were men with disseminated histoplasmosis and adult onset diabetes mellitus not requiring insulin. Patient 217, age 75, received 3 .076 g of amphotericin B over 50 days. For the month prior to study he received daily intravenous infusions of 70 mg of amphotericin B. Patient 220, age 45, received 4 .110 g of amphotericin B over 136 days. He had received a prior course of 2.025 g, ending 9 months before the present course. For the 2 months before this investigation he received intravenous infusions of 70 mg of amphotericin B every other day.
Amphotericin B assay. Serum and urine specimens were bioassayed by using radial growth inhibition of Paecilomyces variotii, as reported previously (5) . The lower limit of accurate detection of amphotericin B by this assay is 0.1 ,g/ml (5) . Urine specimens were kept at 4°C during collection of 24-h samples. Once collected, both urine and serum were stored at -70°C before assay.
Pharmacokinetic analysis. Serum and urine data were analyzed with the SAAM 23 digital computer program developed by Berman and Weiss for multicompartmental analysis (4) . The program was implemented on a model 6400 Control Data Corp. Computer. Preliminary analyses indicated that systematic errors were apparent when an attempt was made to model the kinetics of amphotericin B distribution with a single two-compartment system. However, only apparently random deviations between the experimental data and the computer-calculated results were evident when a three-compartment system was used. A mamillary model was chosen since it is the three-compartment model most commonly selected to describe drug pharmacokinetics and for theoretical reasons presented in the discussion (Fig. 1) .
The assumption was made that, since the patients were studied at the end of their treatment, they were at steady state with respect to their amphotericin B serum and peripheral compartment concentrations. Recovery of amphotericin B excreted in urine was expressed as the rate of renal excretion of amphotericin B (dU/dt) at the midpoint of each collection interval. Where Clr is the renal clearance and S the serum concentration of amphotericin B, dU/dt = Clr S Therefore, renal excretion rate data could be used to determine the renal clearance of amphotericin B as well as to estimate serum amphotericin B concentrations below the analytical sensitivity limit of the assay in case 220 (12) . Intercompartmental clearances (Q) were determined from the product of the distribution volume of a compartment and the intercompartmental transfer rate constant exiting from that compartment (17) .
The computer iteratively adjusted the values of all the parameters of the model to minimize the differences between the theoretical curves describing the serum level and urine excretion rate of amphotericin B and the observed data points. The sum of the squared differences between the data points and the values predicted from the computer fit were 0.0049 for 
RESULTS
The results of the analysis of amphotericin B pharmacokinetics in two patients are summarized in Table 1 . As can be seen in Fig. 2 , the elimination-phase half-life of amphotericin B is approximately 15 days, largely because of the slow return of amphotericin B from the slowly equilibrating peripheral compartment of the pharmacokinetic model (Fig. 1) . The (Fig. 3) . Although the miniimum inhibitory concentration for Cryptococcus neoformans and Candida albicans has been reported to range between 0.05 and 1.56 ,ug/ml (8) initial amphotericin B serum levels that would be expected if case 220 were treated in this fashion are included in Fig. 3 clearance in the two patients, approximating the 30 relative hemodialytic clearances of these two compounds (6) . These results are consistent with the view that amphotericin B excretion in urine results from glomerular filtration and is restricted by the greater than 90% protein binding of this drug (6) . The data also suggest that impaired renal function would not significantly prolong the elimination half-life of amphotericin B if nonrenal elimination pathways were unaffected by the uremic state. In fact, limited experience has demonstrated that serum amphotericin B concentrations are not unexpectedly increased in patients with impaired renal funcfirst4daysof tion (5), or even in anephric patients (6, 10) .
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